Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Change in Account Payables (2016 - 2025)

Historic Change in Account Payables for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Q4 2025 value amounting to $15.3 million.

  • Arrowhead Pharmaceuticals' Change in Account Payables rose 39732.81% to $15.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $18.5 million, marking a year-over-year increase of 8487.39%. This contributed to the annual value of $6.3 million for FY2025, which is 21354.77% up from last year.
  • Latest data reveals that Arrowhead Pharmaceuticals reported Change in Account Payables of $15.3 million as of Q4 2025, which was up 39732.81% from -$15.4 million recorded in Q3 2025.
  • In the past 5 years, Arrowhead Pharmaceuticals' Change in Account Payables ranged from a high of $28.0 million in Q3 2023 and a low of -$15.4 million during Q3 2025
  • For the 5-year period, Arrowhead Pharmaceuticals' Change in Account Payables averaged around $2.4 million, with its median value being -$54000.0 (2021).
  • Its Change in Account Payables has fluctuated over the past 5 years, first soared by 128453.39% in 2022, then crashed by 50149.61% in 2023.
  • Arrowhead Pharmaceuticals' Change in Account Payables (Quarter) stood at -$5.4 million in 2021, then skyrocketed by 61.55% to -$2.1 million in 2022, then tumbled by 501.5% to -$12.5 million in 2023, then skyrocketed by 124.62% to $3.1 million in 2024, then soared by 397.33% to $15.3 million in 2025.
  • Its last three reported values are $15.3 million in Q4 2025, -$15.4 million for Q3 2025, and $23.4 million during Q2 2025.